| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 1,802 | 2,149 | 2,688 | 3,765 |
| Pretax income (loss) | 15,874 | -38,818 | -39,842 | -29,113 |
| Benefit from (provision for) income taxes | -10 | 35 | 34 | 54 |
| Net income (loss) | 15,884 | -38,853 | -39,876 | -29,167 |
| Net loss per common share - basic | 0.14 | -0.35 | -0.36 | -0.27 |
| Net loss per common share - diluted | 0.13 | -0.35 | -0.36 | -0.27 |
| Weighted-average common stock outstanding - basic | 110,966,345 | 110,540,836 | 110,301,256 | 108,507,390 |
| Weighted-average common stock outstanding - diluted | 117,782,074 | 110,540,836 | 110,301,256 | 108,507,390 |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)